Healthcare - Biotechnology - NASDAQ - US
$ 2.27
-3.4 %
$ 128 M
Market Cap
-1.92
P/E
CASH FLOW STATEMENT
-51.2 M
OPERATING CASH FLOW
29.9 M
INVESTING CASH FLOW
233 K
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Rani Therapeutics Holdings, Inc.
| Net Income | -34 M |
| Depreciation & Amortization | 822 K |
| Capital Expenditures | -1.23 M |
| Stock-Based Compensation | 19 M |
| Change in Working Capital | -2.14 M |
| Others | -36.5 M |
| Free Cash Flow | -52.5 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | |
|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||
| Net Income | (34.0) | (63.3) | (53.1) | (16.7) | (26.6) |
| Depreciation & Amortization | 0.8 | 0.5 | 0.5 | 0.6 | 0.6 |
| Deferred Income Tax | 0 | 0 | 1.1 | 0 | 0 |
| Stock Based Compensation | 19.0 | 15.8 | 22.6 | 0 | 0 |
| Other Operating Activities | (35.0) | 10 K | 0.1 | 0.1 | 81 K |
| Change in Working Capital | (2.1) | 0.5 | (3.4) | 1.0 | (0.2) |
| Cash From Operations | (51.2) | (46.5) | (32.2) | (15.0) | (26.3) |
| INVESTING CASH FLOW | |||||
| Capital Expenditures | (1.2) | (1.6) | (0.5) | (1.2) | (1.6) |
| Other Items | 31.1 | (70.8) | 0 | 0 | 49 K |
| Cash From Investing Activities | 29.9 | (72.4) | (0.5) | (1.2) | (1.5) |
| FINANCING CASH FLOW | |||||
| Common Stock Repurchased | 162 | 626 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 29.6 | (2.8) | 4.2 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0.2 | (0.6) | 86.3 | 68.5 | 0.9 |
| Cash From Financing Activities | 0.2 | 29.0 | 77.1 | 72.7 | 0.9 |
| CHANGE IN CASH | |||||
| Net Change In Cash | (21.1) | (89.9) | 44.4 | 56.5 | (26.9) |
| FREE CASH FLOW | |||||
| Free Cash Flow | (52.5) | (48.1) | (32.8) | (16.2) | (27.8) |